GEFOS Gesellschaft fuer onkologische Studien Dortmund mbH — Clinical Trial Site

9 Registered trials

5 Currently recruiting

Organisation

GEFOS Gesellschaft fuer onkologische Studien Dortmund mbH

Location

Dortmund, Germany

Identifier

ORG-100042989

Address

Am Oelpfad 12, Hörde, 44263, Germany

Departments

Gefos Dortmund
GEFOS Dortmund GmbH
Gemeinschaftspraxis für Hämatologie und Onkologie
Gemeinschaftspraxis Schulte Lipke
Hämatologie und Onkologie
Hämatologie/Onkologie
Medizinisches Zentrum
NA

Clinical trials at this site (9)

Search interface

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting

2025-522860-34-00 Chronic lymphocytic leukemia (CLL) 5 2025-12-16
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting

2024-519152-82-00 Relapsed/Refractory Follicular Lymphoma 5 2025-09-03
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult… Ended

2022-500861-29-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2023-01-12
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet… Ended

2022-502338-20-00 Polycythemia vera 6 2023-07-28
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04